Ariceum Therapeutics
Latest round
- Series A
Last raised
- Mar 2023
Total raised
- $25M
Investors
- 3
About Ariceum Therapeutics
Founded in 2021 and based in Berlin, Germany, Ariceum Therapeutics operates as a radiopharmaceutical company that focuses on the diagnosis and precision treatment of neuroendocrine and aggressive and difficult-to-treat specific cancers. The company was launched in 2021 following the acquisition of all rights to its flagship product from subsequent shareholder, Ipsen. Ariceum Therapeutics has operations in Germany and is active across Europe, North America, and Australia. The company offers novel medicines for systemic targeted radiotherapy (STR) to visualize and treat cancer. Ariceum developed a proprietary peptide derivative, Satoreotide, a radiopharmaceutical drug and an antagonist of the somatostatin type 2 (SST2) receptor that is overexpressed in many cancers, including certain hard-to-treat cancers such as small cell lung cancer (SCLC), high-grade neuroendocrine tumors (NETs) and neuroblastoma, an aggressive, rare type of cancer that occurs mainly in young children. Satoreotide is used as a theranostic for both the diagnosis and treatment of tumors expressing the SST2 receptor. The company's therapeutics pipeline includes SSO110 (NETs), SSO110 (SCLC), and SSO111 (SCLC).
Who invested in Ariceum Therapeutics
3 investors across 1 round
See all investors in Ariceum Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 31, 2023
Amount
$25M
Investors
Questions about Ariceum Therapeutics
Who invested in Ariceum Therapeutics?
Ariceum Therapeutics has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ariceum Therapeutics raised?
Ariceum Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Ariceum Therapeutics last raise money?
Ariceum Therapeutics's most recent round on record is a Series A, in Mar 2023.
What does Ariceum Therapeutics do?
Founded in 2021 and based in Berlin, Germany, Ariceum Therapeutics operates as a radiopharmaceutical company that focuses on the diagnosis and precision treatment of neuroendocrine and aggressive and difficult-to-treat specific cancers.
Where is Ariceum Therapeutics headquartered?
Ariceum Therapeutics is headquartered in Berlin, Germany.
Which VCs invest in companies like Ariceum Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Ariceum Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Ariceum Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.